BioLineRx (BLRX) investor relations material

Company overview and business model

• Clinical-stage biopharmaceutical company focused on oncology and rare diseases, advancing GLIX1 (oral small-molecule for glioblastoma and other cancers) and motixafortide (peptide for stem-cell mobilization and solid tumors).

• GLIX1 is being developed via a collaboration with Hemispherian AS and Tetragon Biosciences Ltd., a subsidiary.

• Motixafortide is out-licensed for most indications globally, with ongoing development in solid tumors and partnerships generating royalties and milestones.

• Operations have shifted focus to development in Israel, reducing cash burn after out-licensing commercialization rights.

Financial performance and metrics

• August 2026 Offering raised approximately $3.75 million gross ($3.3 million net), with additional potential proceeds of $5.6 million if all warrants are exercised for cash.

• As of June 30, 2026, pro forma shareholders' equity was $16.4 million, with total non-current liabilities of $3.2 million.

• Outstanding share count post-offering could reach 4.2 billion ordinary shares, assuming full warrant exercise.

Use of proceeds and capital allocation

• No proceeds from the resale of ADSs by the selling shareholder; proceeds from warrant exercises (if any) will be used for R&D, working capital, and general corporate purposes.

• Management retains broad discretion over allocation of any net proceeds from warrant exercises.